Abstract:Osteosarcoma is a rare type of bone cancer, and half of the cases affect children and adolescents younger than 20 years of age. Despite intensive efforts to improve both chemotherapeutics and surgical management, the clinical outcome for metastatic osteosarcoma remains poor. Transforming growth factor β (TGF-β) is one of the most abundant growth factors in bones. The TGF-β signaling pathway has complex and contradictory roles in the pathogenesis of human cancers. TGF-β is primarily a tumor suppressor that inhibits proliferation and induces apoptosis of premalignant epithelial cells. In the later stages of cancer progression, however, TGF-β functions as a metastasis promoter by promoting tumor growth, inducing epithelial-mesenchymal transition (EMT), blocking antitumor immune responses, increasing tumor-associated fibrosis, and enhancing angiogenesis. In contrast with the dual effects of TGF-β on carcinoma (epithelial origin) progression, TGF-β seems to mainly have a pro-tumoral effect on sarcomas including osteosarcoma (mesenchymal origin). Many drugs that target TGF-β signaling have been developed: neutralizing antibodies that prevent TGF-β binding to receptor complexes; ligand trap employing recombinant Fc-fusion proteins containing the soluble ectodomain of either type II (TβRII) or the type III receptor ((TβRIII), preventing TGF-β from binding to its receptors; antisense nucleotides that reduce TGF-β expression at the transcriptional/translational level; small molecule inhibitors of serine/threonine kinases of the type I receptor (TβRI) preventing downstream signaling; and vaccines that contain cell lines transfected with TβRII antisense genes, or target furin convertase, resulting in reduced TGF-β signaling. TGF-β antagonists have been shown to have effects on osteosarcoma in vitro and in vivo. One of the small molecule TβRI inhibitors, Vactosertib, is currently undergoing a phase 1/2 clinical trial to evaluate its effect on osteosarcoma. Several phase 1/2/3 clinical trials have shown TGF-β antagonists are safe and well tolerated. For instance, Luspatercept, a TGF-β ligand trap, has been approved by the FDA for the treatment of anemia associated with myeloid dysplastic syndrome (MDS) with ring sideroblasts/mutated SF3B1 with acceptable safety. Clinical trials evaluating the long-term safety of Luspatercept are in process.

Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway

Telocinobufagin inhibits osteosarcoma growth and metastasis by inhibiting the JAK2/STAT3 signaling pathway.

CD47 Blockade Inhibits Tumor Progression Human Osteosarcoma in Xenograft Models

Osteosarcoma cell proliferation suppression via SHP-2-mediated inactivation of the JAK/STAT3 pathway by tubocapsenolide A

Cyclovirobuxine D Inhibits the Growth of Osteosarcoma Cells Through the Induction of Autophagy Flux Arrest by Promoting Lysosomal Acidification

T52 Attenuates Oncogenic STAT3 Signaling and Suppresses Osteosarcoma.

Toosendanin Demonstrates Promising Antitumor Efficacy in Osteosarcoma by Targeting STAT3

Targeting transforming growth factor beta signaling in metastatic osteosarcoma

Discovery of 2-Amino-3-cyanothiophene Derivatives As Potent STAT3 Inhibitors for the Treatment of Osteosarcoma Growth and Metastasis.

(S)-10-Hydroxycamptothecin Inhibits EMT-evoked Osteosarcoma Cell Growth and Metastasis by Activating the HIPPO Signaling Pathway

Small Molecule TSC01682 Inhibits Osteosarcoma Cell Growth by Specifically Disrupting the CUL4B-DDB1 Interaction and Decreasing the Ubiquitination of CRL4B E3 Ligase Substrates.

Targeting the Wnt/β-catenin pathway in human osteosarcoma cells

Icariin Inhibits Growth Of Human Osteosarcoma Cells By Inducing Apoptosis Via Downregulation Of Beta-Catenin Signaling

Inhibition of the Wnt-β-catenin and Notch Signaling Pathways Sensitizes Osteosarcoma Cells to Chemotherapy.

Anticarin-β shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis

Caudatin Inhibits the Proliferation, Invasion, and Glycolysis of Osteosarcoma Cells via the Wnt/ β- Catenin Pathway

Cooperative blockade of FLT3 and ALK synergistically suppresses growth of osteosarcoma

Anticarin-beta shows a promising anti-osteosarcoma effect by specifically inhibiting CCT4 to impair proteostasis

Sulfatinib, a novel multi-targeted tyrosine kinase inhibitor of FGFR1, CSF1R, and VEGFR1-3, suppresses osteosarcoma proliferation and invasion via dual role in tumor cells and tumor microenvironment

Abstract 7156: Targeting the β-catenin signaling axis in osteosarcoma

Tectorigenin Inhibits Osteosarcoma Cell Migration Through Downregulation of Matrix Metalloproteinases in Vitro